↓ Skip to main content

Drug Desensitization in the Management of Hypersensitivity Reactions to Monoclonal Antibodies and Chemotherapy

Overview of attention for article published in BioDrugs, August 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 X users

Citations

dimensions_citation
44 Dimensions

Readers on

mendeley
55 Mendeley
Title
Drug Desensitization in the Management of Hypersensitivity Reactions to Monoclonal Antibodies and Chemotherapy
Published in
BioDrugs, August 2013
DOI 10.1007/s40259-013-0066-x
Pubmed ID
Authors

Veronica Mezzano, Pedro Giavina-Bianchi, Matthieu Picard, Joana Caiado, Mariana Castells

Abstract

Hypersensitivity reactions to monoclonal antibodies and chemotherapy, which may vary in severity from mild to life-threatening, can lead to their discontinuation and replacement by alternative agents that are often less effective, more toxic, and/or more expensive. Drug desensitization has emerged as the best treatment modality capable of allowing re-introduction of the hypersensitivity reaction-inducing medication in highly sensitized patients in need of first line therapies. In recent years, the availability of new anti-neoplastic drugs and therapeutic monoclonal antibodies has increased, as has the potential for hypersensitivity reactions. Development of desensitization protocols for these new medications requires a careful assessment of the potential risks and benefits. The purposes of this review are to provide an overview of the presentation of hypersensitivity reactions amenable to desensitization and to increase awareness of the indications for and outcomes of desensitization protocols. Rapid drug desensitization has proven to be a safe and effective way of administering first line therapy to patients with hypersensitivity reactions, providing an extremely powerful treatment modality for patients for whom alternative drugs are deemed unacceptable. Rapid drug desensitization protocols should be administered only by highly trained allergists and nurses who have experience in determining which reactions are amenable to desensitization, and can identify high risk patients and provide them with appropriate care. Efforts should be made to increase awareness of the remarkable safety and efficacy of rapid drug desensitization among non-allergists, especially in the fields of oncology and rheumatology, so as to favor its universal application. Development of desensitization units to provide state-of-the-art care is possible only through coordinated teamwork.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Korea, Republic of 1 2%
Spain 1 2%
Unknown 53 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 15%
Researcher 7 13%
Student > Master 7 13%
Student > Postgraduate 6 11%
Professor 3 5%
Other 9 16%
Unknown 15 27%
Readers by discipline Count As %
Medicine and Dentistry 22 40%
Pharmacology, Toxicology and Pharmaceutical Science 5 9%
Nursing and Health Professions 4 7%
Computer Science 2 4%
Biochemistry, Genetics and Molecular Biology 1 2%
Other 5 9%
Unknown 16 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 September 2013.
All research outputs
#14,759,250
of 22,719,618 outputs
Outputs from BioDrugs
#496
of 645 outputs
Outputs of similar age
#118,783
of 199,368 outputs
Outputs of similar age from BioDrugs
#5
of 9 outputs
Altmetric has tracked 22,719,618 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 645 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 199,368 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.